Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Persistent Asthma

Interventions

DRUG: QAW039 capsules once daily for 28 days
DRUG: Placebo to QAW039 capsules once daily for 28 days
DRUG: Fluticasone propionate inhaler twice daily for 28 days

Sponsor

Novartis Pharmaceuticals